share_log

EQT, Genie Energy And Other Big Stocks Moving Lower On Monday

Benzinga ·  Mar 11 10:37

U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday.

Shares of EQT Corporation (NYSE:EQT) fell sharply during Monday's session after the company announced that it entered into a definitive merger agreement to acquire Equitrans Midstream.

EQT shares fell 8.4% to $34.37 on Monday.

Here are some other big stocks recording losses in today's session.

  • Ventyx Biosciences, Inc. (NASDAQ:VTYX) shares tumbled 18.5% to $8.09. Ventyx Biosciences reported clinical data for its NLRP3 inhibitor portfolio and issued pipeline updates at Virtual Investor Event.

  • MoneyLion Inc. (NYSE:ML) dipped 15% to $63.36.

  • Genie Energy Ltd. (NYSE:GNE) declined 12% to $16.67 following fourth-quarter results.

  • Nanobiotix S.A. (NASDAQ:NBTX) dipped 9.8% to $6.35.

  • Pagaya Technologies Ltd. (NASDAQ:PGY) fell 9.6% to $16.54.

  • Bitfarms Ltd. (NASDAQ:BITF) fell 9% to $2.4290. Bitfarms purchased additional miners to reach 21 EH/s in 2024.

  • Quantum-Si incorporated (NASDAQ:QSI) declined 9% to $2.03.

  • Super Micro Computer, Inc. (NASDAQ:SMCI) dipped 8.8% to $1,039.60.

  • MannKind Corporation (NASDAQ:MNKD) dipped 8.7% to $4.81. MannKind announced initial meal challenge data from INHALE-3 Phase 4 U.S. trial comparing afrezza head-to-head with multiple daily injections and insulin pumps.

  • Applied Therapeutics, Inc. (NASDAQ:APLT) fell 8.4% to $6.35.

  • Poseida Therapeutics, Inc. (NASDAQ:PSTX) declined 8.1% to $3.74.

  • Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) fell 7.6% to $30.90. Arrowhead Pharmaceuticals recently announced that it initiated its Phase 1/2a study of ARO-DM1 for the treatment of type 1 myotonic dystrophy.

  • Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) dipped 7.6% to $10.31. Arcutis promoted Todd Tucker to Chief Human Resources Officer.

  • Carvana Co. (NYSE:CVNA) fell 6.3% to $79.96.

  • Celestica Inc. (NYSE:CLS) fell 5.7% to $43.45. Cormark Securities analyst Jesse Pytlak initiated coverage on Celestica with a Buy rating and announced a price target of $56.

  • NOVONIX Limited (NYSE:NVX) fell 5.2% to $2.37.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment